text:
24 augustus 2017: zie ook dit artikel:
en dit artikel:
27 september 2011: toegevoegd onderaan een nieuwe studie die bewijst dat een vergelijkbaar middel everolimus goed werkt bij gevorderde nierkanker.
24/08 Bron: Medscape en verschillende gepubliceerde fase II en fase III studies
Wetenschappers en oncologen pleiten voor een eerstelijns behandeling van uitgezaaide nierkanker met tyrosine kinase inhibitor (TKI) sunitinib voor uitgezaaide niercelkanker (CCRCC) en de mTOR inhibitor, temsirolimus, voor extra risicovolle CCRCC patienten. Dit voorstel wodt gedaan na resultaten uit enkele fase III studies met een behandeling van tyrosine kinase inhibitor (TKI) sunitinib en/of mTOR inhibitor, temsirolimus welke significant een betere overleving geven dan de nu gehanteerde standaard behandeling met interferon (IFN) en/of interleukin (IL)-2,
Nicholas J. Vogelzang, MD
The American Society of Clinical Oncology (ASCO) 2006 Annual Meeting was remarkable for featuring 2 phase 3 trials that appear poised to change the standard of care for the treatment of advanced renal cell carcinoma (RCC). Evidence was presented for the use of the tyrosine kinase inhibitor (TKI) sunitinib as first-line therapy for metastatic clear cell cancers (CCRCC) and for the mTOR inhibitor, temsirolimus, for poor-risk CCRCC patients. Indeed, a targeted therapy approach to RCC has become increasingly viable, as promising data also emerged in other studies with these agents, as well as with other TK and mTOR inhibitors.
Metastatic CCRCC has a median survival of 9-15 months, with significant variability depending on a variety of clinical and pathologic features. For almost 20 years, standard off-protocol therapy for metastatic CCRCC was interferon (IFN) or interleukin (IL)-2, but approval by the US Food and Drug Administration (FDA) of the TKIs sorafenib and sunitinib in December 2005 and January 2006, respectively, signaled a change in approach. Sorafenib, which inhibits the vascular endothelial growth factor (VEGF) pathway and c-RAF kinase isoforms, was approved based on substantial improvement in progression-free survival (PFS) seen in a randomized phase 2 trial[1] and in a placebo-controlled phase 3 trial.[2] Both trials were conducted in patients with prior cytokine (or other) therapy. Sunitinib, which inhibits the VEGF and platelet-derived growth factor (PDGF) pathways, was approved based on impressive response rates and prolonged time to progression (using historical controls) in 2 phase 2 trials.[3,4] These trials were also conducted in patients with prior cytokine (or other) therapy. The 2 practice-changing trials presented at ASCO looked at previously untreated patients.
Patients with RCC are classified as good, intermediate, or poor risk, according to a series of factors. The Memorial Sloan-Kettering Cancer Center (MSKCC)[5] risk group categorization defines the 5 poor risk features as a performance status < 80, a serum calcium > 10 (when corrected for albumin), a hemoglobin below normal, absence of a prior nephrectomy, and a lactate dehydrogenase > 1.5 times normal. Other studies[6] from the Cleveland Clinic, the Eastern Cooperative Oncology Group, UCLA, and the Group Francois d'Immunotherapie have used slightly different parameters, but all were able to identify similar prognostic groupings. Risk stratification was particularly important in the temsirolimus trial presented at ASCO
. Targeted Therapy as First-Line Treatment for Renal Cell Cancer: Results From Key Phase 3 Trials Sunitinib
In a plenary session, Motzer and colleagues[7] reported the results of a phase 3 trial of sunitinib vs IFN as first-line therapy in 750 patients with good- and intermediate-risk CCRCC, as assessed by MSKCC risk group categorization. To qualify for the study, patients could have no more than 2 of the poor-risk features.
The primary end point was PFS, with secondary end points of patient-related outcomes, overall survival, response rate, and adverse events/safety. The trial had a 90% power to detect a 35% improvement in median PFS from 20 weeks to 27 weeks. This report was a planned analysis of the PFS end point. Patients with good performance status and who had a good or intermediate prognosis were randomized 1:1 to receive oral sunitinib 50 mg/day for 4 weeks followed by a 2-week off period (6-week cycles) or IFN 9MU subcutaneously 3 times weekly
The treatment arms were well balanced; patients had a median age of 60 years and 90% had undergone prior nephrectomy. Approximately 35% had good-risk disease, 58% had intermediate-risk disease, and 7% had poor-risk disease. The median PFS was 11 months for the sunitinib arm vs 5 months for the IFN arm (hazard ratio 0.415, P < .000001). The objective response rate assessed by the investigators was 37% for sunitinib vs 9% for IFN (P < .000001), while the independent third party review recorded an objective response rate of 31% vs 6% (P < .000001). There was only 1 complete response (in the sunitinib arm).
At the time of the report, 66% of sunitinib patients were remaining on study compared with only 34% of the IFN patients. All subgroups benefited from sunitinib, including the poor-risk patients (HR 0.53). All adverse events were more common in the IFN arm, except diarrhea, hand foot syndrome, and hypertension, which were more common in the sunitinib arm. Adverse events leading to withdrawal from the study occurred in 8% of patients on sunitinib and 13% on IFN. Only 1% of patients on the sunitinib arm withdrew consent while 8% on the IFN arm withdrew consent. Although survival end points were still premature, the HR was 0.65 (P < .02) in favor of sunitinib. The investigators concluded that sunitinib was the new standard of care for first-line treatment of metastatic CCRCC.
In the second plenary presentation, Hudes and colleagues[8] assessed the role of temsirolimus, an inhibitor of the protein mTOR, which regulates nutritional needs of the cell. As the controller of the nutritional flow in the cell, mTOR also regulates cell growth and angiogenesis by downregulating or upregulating a variety of proteins, including hypoxia inducible factor (HIF). Upregulated HIF and the proteins it regulates occur frequently in renal cancer cells. Sirolimus (rapamycin) is an FDA-approved mTOR inhibitor used to inhibit allograft rejection, and temsirolimus is one of its analogues. Previous studies[9,10] suggested that temsirolimus was most effective in poor-risk patients (who account for 20% to 30% of patients with metastatic CCRCC) and established recommended doses. As a result, the current trial was designed for CCRCC patients with at least 3 or more of 6 poor-risk features (the 5 from the MSKCC criteria plus having more than 1 metastatic site).
The trial randomized 626 patients in a 1:1:1 ratio to 1 of 3 arms: IFN up to 18MU subcutaneously 3 times weekly, temsirolimus 25 mg/week, or a combination of temsirolimus 15 mg/week plus IFN 6MU 3 times weekly. The trial was powered to compare the temsirolimus arms with the IFN alone arm. It had an 80% power to detect a 40% improvement in median survival times from 4.9 months with IFN to 6.9 months with temsirolimus. This report is based on the second planned interim analysis.
Of the 626 patients enrolled on the temsirolimus study, 442 died. The arms were well balanced, with a slightly lower-risk group of patients than expected (only 74% were poor risk by MSKCC criteria). The survival of patients in the temsirolimus-alone arm was 10.9 months, compared with 7.3 months for the IFN-only arm (HR 0.73, P < .007). The survival of patients in the combined arm (temsirolimus + IFN) was 8.4 months (HR .95, P = .69). Objective responses occurred in 7%, 9%, and 11% of patients in the IFN, temsirolimus, and combination arms, respectively. Any toxicity of greater than or equal to grade 3 was seen in 69% of patients on temsirolimus vs 85% to 87% of patients on the 2 IFN-containing arms. Grade 3 toxicity was primarily asthenia, which occurred less frequently in the temsirolimus arm (12%) than in the 2 IFN arms (27% and 30%, respectively). Grade 3 dyspnea was infrequently (8% to 11%) seen in all 3 arms. Rash was more common on the temsirolimus arm (37%, vs 5% on IFN and 16% on the combination arm). Likewise, adverse events leading to withdrawal from the study occurred in 7%, 14%, and 22% of patients on temsirolimus, IFN, and the combination arms, respectively.
Commentary on the 2 Presentations
Dr. Michael Atkins, of the Beth Israel Hospital and the Dana-Farber Cancer Center in Boston, commented on the 2 plenary presentations. He stated that both sunitinib and temsirolimus are now proven to be better than IFN in the first-line treatment of advanced RCC, and that temsirolimus is the first new agent to improve overall survival in poor-risk patients. He cautioned, however, that while the activity was robust, no complete responses were seen, that survival benefit was not yet proven for sunitinib, and that there were no predictors of response to sunitinib. He mentioned a small study in which detectable levels of phospho S6 kinase (a protein downstream of mTOR) appears to predict for response to temsirolimus in 4 of 10 patients, but he noted that understanding and overcoming the problem of drug resistance or the mechanism of tumor escape from drug control is the next needed step. Other major questions remain, including the role of adjuvant therapy, the role of cytoreductive nephrectomy, the problems of central nervous system metastases, and treatment of patients with tumors of non-clear-cell histologies. Dr. Atkins concluded by encouraging accrual to the many trials open for CCRCC.
Further Evidence for the Role of Targeted Therapies in RCC
A number of other presentations on sunitinib sought to refine its optimal use, whether through dosing schedule, sequencing, or as combination therapy. For example, Rini and colleagues presented data indicating that sunitinib had substantial activity in metastatic RCC patients who were bevacizumab refractory (defined as disease progression within 3 months of bevacizumab). They treated 60 such patients with sunitinib and found that 74% had some degree of tumor shrinkage (16% partial response and 58% less than 50% regression). The median PFS was 24 weeks, and 57% remained on treatment at the time of the report.
De Mulder and colleagues showed that continuous oral dosing of sunitinib at 37.5 mg/day (in contrast to the usual dosing schedule of 50 mg/day for 4 weeks with a 2-week rest period) was safe and induced tumor shrinkage in 33 of the first 40 evaluable patients (82%). Houk and colleagues used the pharmacokinetic data collected from the 2 large phase 2 trials of sunitinib[3,4] and reported that improved clinical response and longer time to tumor progression were noted in patients with greater drug exposure as measured by AUC (area under the curve). Finally, Ronnen and colleagues combined sunitinib with gefitinib in a phase 1 trial in RCC and determined the recommended phase 2 dose to be 37.5 mg/day of sunitinib and 250 mg/day of gefitinib. Responses were seen in 5 of the 11 patients.
mTOR Inhibitors
Although temsirolimus is not approved, the Hudes study is the first to document the safety, efficacy, and survival advantage of this agent, which is representative of a novel class of agents, the mTOR inhibitors. The role of mTOR inhibitors in metastatic CCRCC is likely to grow, and a number of presentations at the ASCO meeting demonstrated the various approaches to mTOR inhibition currently under study. Amato and colleagues showed that the orally bioavailable mTOR inhibitor everolimus, when given at a dose of 10 mg/day, induced a response in 7 of 25 patients with metastatic CCRCC. More than 86% of patients remained on that study beyond 3 months. This agent also showed activity in advanced endometrial cancer. The original mTOR inhibitor, rapamycin, is being examined for anticancer activity in 2 phase 1 trials.[17,18] Of note, mTOR inhibitors act synergistically with angiogenesis inhibitors, and phase 1 trials of several combinations, including those looking at bevacizumab and everolimus, are underway.
The second TKI approved for use in metastatic RCC is sorafenib, and a number of studies regarding its use in RCC were discussed.[20-25] Although phase 2 data from a trial by Escudier of sorafenib vs IFN were not yet mature enough to be presented, Eisen and colleagues reported an update of the 900 + patient TARGET study presented at ASCO in 2005 by Escudier and colleagues. That trial now shows a trend for a survival advantage for the sorafenib arm compared with placebo at both the first and second (of 4) planned interim data analyses. Ryan and colleagues presented a phase 2 trial of sorafenib plus IFN conducted by the Southwest Oncology Group showing an objective response rate of 18%.
Sosman and colleagues reported preliminary encouraging results of a phase 1/2 trial of bevacizumab combined with sorafenib. Although neither drug could be given at the recommended phase 2 dose, responses were seen in 8 of the 18 RCC patients. Data concerning the synergistic toxicity and probable efficacy of sorafenib plus bevacizumab were also presented by the National Cancer Institute group, which noted encouraging responses in RCC and ovarian cancer patients.
The question of cross resistance among the TKIs was partially addressed by Tamaskar and colleagues. In a retrospective review, the Cleveland Clinic group showed that of 4 patients progressing after prior TKI therapy, all had tumor shrinkage when switched to an alternative oral TKI antiangiogenic agent: sunitinib to sorafenib (n=1), sorafenib to sunitinib (n=2), and axitinib to sunitinib (n=1).
The results presented at ASCO 2006 are important because they define new standards of care for patients with good-, intermediate-, and poor-risk CCRCC. Sunitinib should now be recommended as first-line therapy for good- and intermediate-risk (and probably poor-risk disease as well) metastatic CCRCC patients. Level 1 evidence continues to support use of sorafenib as second-line therapy after progression on cytokine therapy. It is emerging as an agent to combine with bevacizumab or IFN as first-line therapy, and it may be non-cross-resistant with sunitinib. Both agents are being studied as adjuvant therapy after resection of locally advanced RCC. Temsirolimus (and possibly other mTOR inhibitors) is a promising new agent in metastatic RCC and, when available, should be used in patients with poor-risk disease or combined with angiogenesis inhibitors.
Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512. Abstract Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl. 2005;3:226. Abstract 794.
Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2005;23:380s. Abstract 4508.
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24. Abstract
Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463. Abstract
Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol. 2002;13:1460-1468. Abstract
Motzer RJ, Huston TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:2s. Abstract LBA3.
Hudes G, Carducci M, Tomczak P, et al. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line poor-prognosis patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:2s. Abstract LBA4.
Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918. Abstract
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296. Abstract
Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:222s. Abstract 4522
De Mulder PH, Roigas J, Gillessen S, et al. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:223s. Abstract 4529
. Houk BE, Amantea M, Motzer RJ, et al. Pharmacokinetics and efficacy of sunitinib in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:224s. Abstract 4531.
Ronnen EA, Kondagunta GV, Lau C, et al. A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:225s. Abstract 4537.
Amato RJ, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:224s. Abstract 4530.
Oza AM, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer -- NCIC IND 160. Proc Am Soc Clin Oncol. 2006;24:121s. Abstract 3003.
Jimeno A, Kulesaza P, Cusatis G, et al. Pharmacodynamic-guided, modified continuous reassessment method (mCRM)-based, dose finding study of rapamycin in adults patients with solid tumors. Proc Am Soc Clin Oncol. 2006;24:125s. Abstract 3020
. Cohen EE, Moshier K, Innocenti F, et al. Phase I study of rapamycin in combination with CYP3A4 modifier, ketoconazole, in patients with advanced malignancies. Proc Am Soc Clin Oncol. 2006;24:136s. Abstract 3061.
Zafar Y, Bendell J, Lager J, et al. Preliminary results of a phase I study of bevacizumab in combination with everolimus in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 2006;24:145s. Abstract 3097.
Sosman JA, Flaherty K, Atkins MB, et al. A phase I/II trial of sorafenib with bevacizumab in metastatic renal cell cancer patients. Proc Am Soc Clin Oncol. 2006;24:128s. Abstract 3031.
Gao X, Reddy P, Dhanda R, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:242s. Abstract 4604.
Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon in treatment-naive patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2006;24:217s. Abstract 4501.
Eisen T, Bukowski RM, Staehler M, et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma: impact of crossover on survival. Proc Am Soc Clin Oncol. 2006;24:223s. Abstract 4524.
Ryan CW, Goldman BH, Lara Jr PN, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon--alpha2b as first-line therapy for advanced renal cell carcinoma: SWOG 0412. Proc Am Soc Clin Oncol. 2006;24:223s. Abstract 4525.
Dhanda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. Proc Am Soc Clin Oncol. 2006;24:225s. Abstract 4534.
Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol. 2005;23:380s. Abstract LBA4510.
Azad NS, Posadas EM, Kwitkowski VE, et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. Proc Am Soc Clin Oncol. 2006;24:121s. Abstract 3004.
Tamaskar I, Shaheen P, Wood L, et al. Antitumor effects of sorafenib and sunitinib in patients with metastatic renal cell carcinoma who had prior therapy with anti-angiogenic agents. Proc Am Soc Clin Oncol. 2006;24:240s. Abstract 4597.
Phase 3 trial of everolimus for metastatic renal cell carcinoma
Source: Cancer
Article first published online: 19 AUG 2010
DOI: 10.1002/cncr.25219
A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor–tyrosine kinase inhibitors. Final results and analysis of prognostic factors are reported.
Patients with mRCC (N = 416) were randomized (2:1) to everolimus 10 mg/d (n = 277) or placebo (n = 139) plus best supportive care. Progression-free survival (PFS) and safety were assessed to the end of double-blind treatment. Mature overall survival (OS) data were analyzed, and prognostic factors for survival were investigated by multivariate analyses. A rank-preserving structural failure time model estimated the effect on OS, correcting for crossover from placebo to everolimus.
The median PFS was 4.9 months (everolimus) versus 1.9 months (placebo) (hazard ratio , 0.33; P < .001) by independent central review and 5.5 months (everolimus) versus 1.9 months (placebo) (HR, 0.32; P < .001) by investigators. Serious adverse events with everolimus, independent of causality, in ≥5% of patients included infections (all types, 10%), dyspnea (7%), and fatigue (5%). The median OS was 14.8 months (everolimus) versus 14.4 months (placebo) (HR, 0.87; P = .162), with 80% of patients in the placebo arm crossed over to everolimus. By the rank-preserving structural failure time model, the survival corrected for crossover was 1.9-fold longer (95% confidence interval, 0.5-8.5) with everolimus compared with placebo only. Independent prognostic factors for shorter OS in the study included low performance status, high corrected calcium, low hemoglobin, and prior sunitinib (P < .01).
These results established the efficacy and safety of everolimus in patients with mRCC after progression on sunitinib and/or sorafenib. Cancer 2010. © 2010 American Cancer Society.
Plaats een reactie ...
Reageer op "TKI -Tyrosine kinase inhibitor (TKI) sunitinib wordt als eerstelijns behandeling voorgesteld voor uitgezaaide niercelkanker (CCRCC) en de mTOR inhibitor, temsirolimus, voor risicovolle CCRCC patienten na opmerkelijke resultaten uit twee fase III studies."
Gerelateerde artikelen
- ASCO 2020: belangrijke abstracten specifiek gerelateerd aan nierkanker aanbevolen door Dr. Sumanta Pal
- Verhoogde bloedwaarden van γ-Glutamyltransferase (GGT) geeft een sterk negatieve prognose op overall overleving, 16 vs 38 maanden), voor patienten met uitgezaaide nierkanker
- Immuuntherapie met Atezolizumab plus Avestin - bevacizumab geeft betere progressievrije ziekte en overall overleving dan sunitinib bij patienten met gevorderde uitgezaaide nierkanker
- Avelumab plus Axitinib geeft veel betere progressievrije overleving (plus 5 maanden) dan sunitinib als eerstelijns behandeling bij nog niet behandelde uitgezaaide nierkanker.
- Pembrolizumab plus Axitinib geeft betere overleving op 1 jaar (plus 11 procent) en betere progressievrije ziekte dan met sunitinib voor nog niet behandelde uitgezaaide nierkanker
- immuuntherapie met axitinib (Inlyta®) en pembrolizumab (Keytruda®) bij gevorderde nog onbehandelde nierkanker verdubbelt progressievrije ziekte (10 vs 20 maanden)
- Immuuntherapie met rocapuldencel-T (AGS-003), een vorm van dendritische celtherapie met individuele T-cel stimulatie geeft uitstekende resultaten bij nieuwe patienten met uitgezaaide nierkanker
- HIFU - High Focused Ultra Sound succesvol toegepast bij niertumoren.
- Interferon Alpha als aanvullende therapie ter voorkoming van een recidief faalt bij operabele nierkankerpatienten
- Nexavar(R) (sorafenib tosylate) geeft significante langere overleving en remt de groei van nierkanker in vergelijking met placebo, aldus enkele nieuwe fase II en fase III studies
- Nivolumab (Obvio) alleen en samen met ipilimumab (Yervoy) geeft uitstekende resultaten bij gevorderde niercelkanker ook in vergelijking met sunitinib
- Nivolumab een immuuntherapeutisch anti PD medicijn geeft uitstekende resultaten bij vergevorderde nierkanker versus everolimus en krijgt van FDA goedkeuring voor gebruik als medicijn
- Operatieve verwijdering van uitzaaiingen vanuit nierkanker zorgt voor een jarenlange levensverlenging van 3 tot 12 jaar in vergelijking met geen operatie
- RFA - Radio Frequency Ablation uitgevoerd laroscopisch of met gesloten huid en CT geleid geeft zelfde vergelijkbare resultaten op ziektevrije tijd en complicaties
- TKI -Tyrosine kinase inhibitor (TKI) sunitinib wordt als eerstelijns behandeling voorgesteld voor uitgezaaide niercelkanker (CCRCC) en de mTOR inhibitor, temsirolimus, voor risicovolle CCRCC patienten na opmerkelijke resultaten uit twee fase III studies.
- Zometa - Zoledronic Acid: Een overzichtstudie van drie gerandomiseerde dubbelblind gecontroleerde studies bewijst dat Zometa - Zoledronic Acd veruit betere resultaten geeft dan APD - Pamidronate bij botproblemen, ook bij botuitzaaiingen vanuit nierkanker,
- Regulier - nierkanker: actuele ontwikkelingen en belangrijke studies binnen de reguliere oncologie: een overzicht


text:
Subscribe to InvestmentKit
Over 98,821 Regular
Most Useful and
Popular Articles
Privacy Policy & Disclaimer of www.Investmentkit.com
State Bank of India Plans
Explore Insurance Section
Useful Articles on Insurance
Explore Others Famous Articles
Government Schemes
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, without your consent, other than for the express purpose of delivering the purchased product or service requested.
Mutual Fund investments are subject to market risks.
Please read the offer document carefully before investing.
Insurance is the subject matter of solicitation.
Disclaimer: The content in this website is purely for Information purposes
only and is not an offer or solicitation of any kind. This content should not
be acted upon without consulting or without the prior advice of your financial
advisor. Nothing in this website should be considered personalized advice
about your investment, real estate, insurance or other personal finance
Online Privacy Policy Only This online privacy policy applies only to information collected through our website and not to information collected offline.Your Consent By using our site, you consent to our online privacy policy.Changes to our Privacy Policy If we decide to change our privacy policy, we will post those changes on this page. Contacting Us If there are any questions regarding this privacy policy you may contact us using the information below. http://www.investmentkit.com3rd Floor,Shankar Market,C.P.delhi, delhi 110001india[email protected]
Most Popular Links
Indian Mutual Funds
Do you like this website? Get
future updates via our Free
Our Network:
Mutual Fund investments
are subject to market risks. Please read the offer document carefully
before investing.

subset: commoncrawl


text:
For most of the country, the real estate market is hot right now. Home prices are as high or higher than they've ever been in many regions of the US, and with demand so high, many homes are getting offers for well above asking price. In some cities, demand is far outpacing supply, which means that people can put just about any house on the market, ask for more than it's worth, and then get offers for even more than they've listed the house at. It's a good time to try and sell, and with so many buyers out there, it looks like that trend will continue for quite some time.
All that said, there are actually still quite a few homeowners out there that are having a difficult time getting their house off the market. Maybe they live in a part of the country where the housing market isn't nearly as hot as it is in cities like San Francisco, or maybe they just have the bad luck of living in an area where a lot of their neighbors are also looking to sell. Whatever the reasons behind why they're unable to sell their home, if they truly want to get it off the market and get a prospective buyer under contract, they're going to have to do some things to make their home stand out.
Such homeowners might consider renovating a portion of their home, finishing a basement, replacing old appliances, or even painting the exterior a different color. Of course, all of those projects take a fair bit of time and cost a pretty penny. One of the less expensive and time-consuming options for such homeowners to consider is installing new custom window treatments in every room of their home. It might seem like a small thing, but new window treatments can really improve the way a home looks and feels. It can improve the home's curbside appeal, draw more attention to certain aspects of the home, improve the lighting in the area here people walk in, and just generally make the home look newer and cleaner. For a fraction of the cost of replacing appliances or painting the exterior of the home, the homeowner can drastically alter the way their home looks and feels, both when someone is standing on the sidewalk outside the home or when they walk into the living room.
When you're a homeowner that's struggling to get your property off the market, you're willing to try anything. Fortunately, sometimes something as inexpensive and quick as putting up new custom window blinds is all you have to do to make your home more appealing to potential buyers. Sometimes it's the small things that make the difference between selling a home and sitting on it for months and months with no end in sight. So, if you're having a hard time getting someone to be interested in your home, visit a window treatment supplier like Shades on Wheels and purchase some new window treatments for your house.


text:
Hat-Trick For Toorak Warrior
May 25, 2018
At each of his last three starts Toorak Warrior has not only risen in class but also in distance - and each time he has done everything asked of him winning each of those races in impressive style.
At Pakenham on Thursday evening the good-looking bay was once again beautifully handled by regular rider Jye McNeil who had the three-year-old travelling sweetly in third position.
Into the clear turning, Toorak Warrior quickly joined the leaders, challenged by those on his inside before getting the upper hand from the 200m - doing a good job stepping up from 1312m to 1600m.
"His sire was a top class miler and he is out of a Carnegie mare," Ryan Griffiths said, noting that the stable were always confident that Toorak Warrior would have no problems with the trip.
"He has always had talent," Ryan continued, "he just wanted to over-race a bit too much in his first campaign but he is now learning how to relax."
"He has come up well an we are really happy with him."
Toorak Warrior, who may now have a freshen to come back for the 1400m of the Silver Bowl Final, is building a great relationship with Jye Neil who was confident heading out to the track, noting that "he was really on the ball before the race."
"And he has just kept improving with each run."


text:
IQS Directory provides an extensive list of agitator manufacturers and suppliers in Maine. Utilize our website to review and source agitator manufacturers with our easy-to-use features which allow you to locate agitator companies that will design, engineer, and manufacture agitators for your exact specifications. Our request for quote forms make it easy to connect with leading agitator manufacturers. View company profiles, website links, locations, phone number, product videos, customer reviews, product specific news articles and other production information. We are a leading manufacturer directory who will connect you with the right manufacturers whether you are looking for batch mixers, drum mixers, or paddle mixers.
As world leaders in industrial mixer manufacturers, KADY® International offers high-performance industrial mixing machinery including inline mixers, high shear mixers, lab mixers and chemical mixers. Featuring a worldwide network of representatives and agents, KADY® International outreaches other industrial mixer companies in consumer reach and accessibility and offers excellent customer service. Agitators in Maine.
Cleveland Mixer serves the chemical, food and pharmaceutical processing industries. Our complete line of high quality industrial mixers is proudly made in the USA. Manufacturers of custom engineered low shear mixers from laboratory to full production scale. Now offering custom engineered bench scale reactor/agitator systems. Please call us with your requirements for a quote. Agitators in Connecticut.
We manufacture static mixers and other plastic products. We have two-component, microsized static mixers for medical applications. Our Ratio-Pak® adhesive dispensing static mixer handles adhesives, sealants, foams, coatings and potting compounds. Ratio-Pak® is used in our HSS spray system. Agitators in Connecticut.
Sonic offers industrial mixers—Colloid Mills, Prop and Rotor-Stator Static Mixers, Continuous Blending Systems plus our patented Sonolator™ Systems to meet a range of mixing and homogenizing needs. The unique Sonolators™ offer continuous in-line processing of difficult emulsions and dispersions. Agitators in Connecticut.
Ashby Cross provides mix heads, dispense heads and static mixers that are disposable and offer reliable and predictable mixing. Agitators in Massachusetts.
Bematek Systems manufactures mixers. Our products include wet mixing and milling equipment such as high-shear in-line mixers and high-speed colloid mills, serving the pharmaceutical, cosmetic, food, specialty chemical, paints and coatings and adhesive industries. We have over 50 years of experience. Agitators in Massachusetts.
Brandywine distributes disposable plastic mixers, dual cartridge systems, manual dispensers and pneumatic dispensers for diverse adhesive applications. Products are commonly used to mix and dispense epoxy, acrylate, polyurethane and other one or two-part materials. For more information, please call. Agitators in Massachusetts.
DeWallace provides a full line of industrial mixers, as well as the capabilities for custom tanks and mixer combinations to cater to specific applications. See our website or call to us today to find the perfect mixer for any need you may have. Agitators in Massachusetts.
J Little Mercer will customize our products to fit your needs. Of our products are mixers, drives, homogenizers, blenders and dryers, blade mixers, pumps, pressure vessels, etc. Since 1969 we have been serving the food, chemical, paint, metal and plastic industries, among others. As we buy and sell used products, our inventory is extensive and our experienced crew is happy to assist you. Agitators in Massachusetts.
Our reliable agitators come fully featured with the strongest motors on the market. Our agitators are very economical and are a smart choice for energy efficiency. We have been in business since 1996 we have a commitment to serve you with the utmost satisfaction. We strive to provide you with the best experiences possible. Our high performance products will never let you down. Please contact us today or visit our website to learn more information! Agitators in Massachusetts.
For over 60 years, we've manufactured a line of high shear industrial mixers --batch, lab, in-line, sanitary, powder/liquid -- for diverse industries such as food, pharmaceutical, cosmetic, chemical, petrochemical and more. Our clients get top customer service, so call us for your industrial mixers. Agitators in Massachusetts.
We guarantee to beat any competitor's price on comparable mixing equipment including lab stirrers, air mixers, drum mixers, tote mixers, biopharm agitators, high shear mixers, XP mixers, mixing impellers & stirring propellers, mix tanks, mixing stands & mix tachometers. Optimized for improved mixing. Agitators in Massachusetts.
Our low-shear agitator, the RotoMAXX II, is designed with a right angle helical bevel gearbox and can handle volumes up to 60,000 gallons. The Rotomixx is a portable/tote agitator with a 316 SS gearbox and bearing frame that provide superior corrosion resistance. Both units are 3-A compliant and can withstand the most stringent CIP, washdown, pressure washing, and steam cleaning environments. See rotomaxx.com or rotomixx.com.Agitators in New Hampshire.
Ross is a manufacturer of industrial mixing, blending and dispersion equipment since 1842. We offer sanitary, standard and custom equipment designed to meet the varied mixing requirements of our customers from virtually all the process industries. Our plants in the United States, China and India are all fully equipped with advanced engineering and production tools. In the US alone, we operate five plants and maintain an 8000-sq.ft. Test & Development Center. Call us or visit our website today! Agitators in New York.
With our 25 years of customer satisfaction and quality equipment, you can be sure Creative Design & Machine can meet your blending, lifting and handling needs. Specifically adapting to your style of blending, be it "V" Shape / Double Cone / Bin or Drum processes, we can design and manufacture to fit your industrial requirements. Such equipment includes the High-Speed Mixing Bar and blending bins. Agitators in New York.
We supply our customers with the largest variety of mixing equipment. Our designs span from lab stirrers to large top-entry tank mixer systems. These mixers are high quality and modular to allow for rapid assembly resulting in satisfactory usability. Our customer service team is eager to guide you in discovering which agitators work best for your facility. Please contact us today for more information! Agitators in New York.
ErtelAlsop is a leading manufacturer of high quality agitators and industrial mixers—static mixers, portable mixers, fixed mount, batch mixers and much more. Industries served by us include chemical, cosmetic, electric utility, food and beverage plus pharmaceutical. Call today! Agitators in New York.
At ITT, we manufacture the following industrial mixers: compact mixers for solids suspension and liquid blending; slow-speed mixers with large-diameter propellers for solids suspension, blending and destratification and submersible mixers, which produce a jet for efficient mixing of volume. Agitators in New York.
For over 50 years, Keith Machinery has been serving the process industry to markets such as cosmetic, pharmaceutical, food, chemical, paint, etc. Some of our workshop specialties include stainless steel and custom fabrication, mixing and blending equipment and kettle and tank agitation systems with homogenization and scrapper options. Check out our website for a full listing of our products. Agitators in New York.
Engineered utilizing advanced Swiss technology, Kinematica serves the U.S. with chemical, biochemical, pharmaceutical, cosmetical & food mixers capable of volumes from 0.1 ml (batch) up to 130,000 L/h (inline) for lab, pilot plant, production & industrial conditions. Achieve results thought to be impossible for homogenizing, dispersing, emulsifying, suspending, size reduction & wet milling. Agitators in New York.
Lightnin is a manufacturer of industrial mixers, agitators and industrial blenders including static mixers, high shear mixers and dispersing equipment. Offers a full-spectrum of impellers and system designs for even the most-diverse applications. Agitators in New York.
Manufacturers of portable rotary drum mixers and agitators. Morse Manufacturing has over 75 years experience and we have consistently been innovators in the drum handling industry. Agitators in New York.
A leading manufacturer of a variety of mixing and blending equipment for batch or continuous processing of bulk food, dairy, chemical, and pharmaceutical products, including: Rotary Batch Mixers, Vee-Cone Blenders, Ribbon/Paddle/Plow Blenders, Fluidized Bed Mixers, Continuous Rotary Blenders and Variable Intensity Blenders. Agitators in New York.
RFI Construction Products manufactures and distributes a full line of equipment, accessories and replacement parts for the specialty cement industry. We are also recognized distributors of mixers and washers for a variety of top machinery manufacturers. Agitators in New York.
Manufacturer of industrial mixers, some of which use ribbon or paddle agitators. Among our products are sanitary, mix-all and power-mix mixers, for dense material, vertical batch, pharmaceutical and/or laboratory markets. If it sounds like we can match your needs, check us out. Agitators in New York.
StaMixCo is a manufacturing company that provides you with the static mixers that you need. Our motionless mixers are made for continuous processing of liquids, gases, slurries and polymers. Among our products are nozzles and filters, blenders and plastic disposable mixers. We can fabricate for you custom and standard static mixers that will meet your requirements. Welcome to StaMixCo! Agitators in New York.
Westfall Manufacturing produces static mixers for water treatment, chemical blending, potable water and more applications. We proudly serve customers such as Anheuser-Busch, Chinet® Company, National Gypsum, Fluid Metering Co. and more. Agitators in Rhode Island.
Auburn, Augusta, Bangor, Bath, Belfast, Biddeford, Brewer, Calais, Caribou, Eastport, Ellsworth, Gardiner, Hallowell, Lewiston, Old Town, Portland, Presque Isle, Rockland, Saco, Sanford, South Portland, Waterville, Westbrook
Androscoggin, Aroostook, Cumberland, Hancock, Kennebec, Knox, Penobscot, Sagadahoc, Waldo, Washington, York


text:
BOBBY asked in Entertainment & MusicMusicClassical · 8 months ago
I am trying to find out the year my Adam Schaaf Piano was manufactured the number is on the Back of the Piano the # is 5103. ?
1 Answer
- MamiankaLv 78 months ago
Between 1890 and 1895. Could be valuable ( not likely unless perfect) or could be potential firewood. You would need a personal appraisal. Do not trust value given by people trying to SELL ones they already have - the prices are inflated.
- Log in to reply to the answers
Still have questions? Get answers by asking now.


text:
Rental Telescope - Hesitant about buying a telescope? Not sure if astronomy is right for you? Rent this 8" Sky-Watcher Dobsonian and enjoy the best show in the universe.
Flexible rental options:
$400.00 deposit required up-front, payable by credit card, interac or cash.
Note: Rentals are for in-store pickup only, and cannot be shipped. A signed rental agreement is required, which can be filled out in-store.
Rental includes a 25mm (48x) and 10mm (120x) eyepiece, a 2x Barlow lens (yielding 96x and 240x), a moon filter, four planetary filters, two different styles of finderscope, red LED flashlight, planisphere (map) and instruction manual.
If you purchase a telescope $200.00 or greater within three (3) month of returning the rental, we'll give you your rental cost back less $40.00 to cover equipment check-out costs and administration.
For example, if you rent this telescope for one week @ $59.99, we'll give you a $39.99 credit towards the purchase of a qualifying telescope.
Overcast protection: If the skies don't cooperate, we'll give you another same-duration rental period on a date that's compatible with you (subject to availability). We really want you to see cool astronomical objects, not clouds. If you decide to buy a scope instead of taking advantage of overcast protection, we'll waive 100% of the rental fee.
According to Canadian astronomy guru Terence Dickinson, the Dobsonian telescope is the closest thing to the ideal beginner's telescope (Nightwatch, 4th edition, page 69). This is due to the outstanding amount of light gathering and simplicity versus the cost.
We totally agree. If you want raw performance, it's hard to beat a Dob. Their point-and-shoot approach gives it an obvious advantage. They also boast the quickest set-up time, so you'll spend more time observing.


text:
Member? Sign in. Not a member? Register for free.
NYC Travel
iOS iPhone Travel
NYC Travel | The App that helps you explore and discover NYC!
The tools you need to experience NYC! Maps, Restaurants, Tickets, Free Stuff To Do and Much More! Everything you need in one single place!
Share the App and help others discover so much from NYC!
Download App Now!
Show More...


text:
This is a stunning unique designer 18 carat gold, diamond and large natural Welo opal from Ethiopia. This is a top quality stone, which has a semi-transparent pale grey background colour, with bright rolling flashes of red, yellow, orange and green across its entire surface.
It is high domed, 18mm by 12mm and of approx. 12.00 carats
It features a small brilliant cut diamond, 1.25mm in diameter.
It is made in polished and textured Solid 18 Ct. Yellow Gold. Laser Hallmarked for Edinburgh 2014.
Overall Length of Pendant: 37mm, Maximum Width: 20mm.
Total Item Weight: 8.02 grams
Please note: A gold chain is NOT included in the sale of this opal and diamond pendant, but is available under a different heading on this website.
A beautiful one-off designer pendant, which has been crafted to the highest standards by a master goldsmith. A unique piece of jewellery, which will bring pleasure to the owner and future generations.


text:
Blog Archives
Boston Celtics – 2013 Preview
Last Season: 39-27, lost Conference Finals to Miami
Starting 5: Rajon Rondo, Courtney Lee, Paul Pierce, Brandon Bass, Kevin Garnett
Bench: Deep in frontcourt and backcourt. Bradley will be able to fill in minutes as PG when healthy as well as possibly starting at SG. Terry in a sixth man roll again. Green getting minutes at SF and PF spots. Fab Melo and Jared Sullinger will get solid minutes also.
Expected Wins: 50-55 wins
Expected Losses: 27-32 losses
Offseason moves:
Players Kept – F Brandon Bass, G Avery Bradley, G Keyon Dooling, F/C Kevin Garnett, F Jeff Green, F Paul Pierce, G Rajon Rondo
Free Agents – G/F Marquis Daniels, G/F Mickael Pietrus
Players Added – F Kris Joseph (draft), C Fab Melo (draft), F Jared Sullinger (draft), C Jason Collins (FA), G Jason Terry (FA), F/C Chris Wilcox (FA), G Courtney Lee (trade)
Players Lost – G Ray Allen (FA), C Ryan Hollins (FA), C Greg Stiemsma (FA), C Jermaine O'Neal (FA), F/C JaJuan Johnson (trade), G E'Twaun Moore (trade), G/F Sasha Pavlovic (trade), F/C Sean Williams (trade)
July 11 Signings
Wednesday, July 11 – Signings that have been formally processed:
- The Brooklyn Nets have re-signed G Deron Williams (5 year contract), F Gerald Wallace (4 year contract) and C Brook Lopez (4 year contract).
- The Denver Nuggets re-signed G Andre Miller.
- The Detroit Pistons signed 2011 draft pick F Kyle Singler to a multi-year deal.
- The Los Angeles Clippers re-signed F Blake Griffin (5 year contract) and signed free agent G Jamal Crawford.
- The Miami Heat signed G Ray Allen and F Rashard Lewis.
- The New York Knicks re-signed G J.R. Smith.
- The Oklahoma City Thunder signed C Hasheem Thabeet.
- The Phoenix Suns offered G Eric Gordon an offer, the New Orleans Hornets have 3 days to match or decline it.
- The San Antonio Spurs re-signed F Tim Duncan and G/F Danny Green.
- The Toronto Raptors offered G Landry Fields to a 3 year contract, the New York Knicks have 3 days to match or decline it.
- The Utah Jazz re-signed G Jamaal Tinsley.


text:
21 Nov 2017 20:18
What did your Mom tell you when you were a kid? I'm sure that it included advice like "eat your vegetables," right? Well, you just don't have time, so what can you do? Vitamins and minerals can fill in where your diet fails you, so check out the tips below.Two of mouse click the following post best sources for vitamin D are exposure to the milk and sun. You should take a supplement with vitamin D if you are not a big milk drinker or do not spend a lot of time in the sun. Vitamin D protects your bones and keeps them from becoming brittle.minerals and Vitamins are a great way to prevent retain and aging that youthful appearance and resilience we had in our younger days. As you get older, you tend to start requiring more nutrients in the form of vitamins and minerals to keep your skin soft, fight off colds and promote energy that we would consume far more quickly by relying only on the foods we eat.Calcium facilitated bone strength. To properly absorb the calcium, although your body needs vitamin D. There are several ways to get the necessary vitamin D, including supplements, food and even sunlight. Any of these help your body absorb calcium.When buying fat-soluble vitamins, like omega-3, it is a good idea to store them in the refrigerator. Since they contain fat, improper store can cause them to become rancid. Make sure to keep them away from heat and light because this can break them down and make them ineffective also.Coenzyme Q-10 is used to treat vessel and heart conditions, including angina, congestive heartfailure and diabetes, gum disease and high blood pressure. This potent formula strengthens immune systems and increases energy. Patients can get the substance naturally in seafood and meat however, most prefer to take a Coenzyme Q-10 supplement.It's true that your body requires fruits and veggies for their nutrients however, know that fresh products are much better than those that are canned. Though you want to eat a healthy diet, you should also consider taking a quality multivitamin and/or mineral supplements to enhance your diet.If you give your young children vitamin supplements make sure to keep them stored out of reach of the children. Most children's vitamins are flavored and very similar to candy. This is to encourage children to take them. It can also lead to children confusing them with candy, however. Since it is possible to overdose on vitamins, keep them out of reach.While taking a child's gummy supplement may taste great, you will need more than one of these each day. An adult vitamin dosage Buy Vigrx Plus is higher than that of a child's, so you need to make the necessary calculations. Make sure you read the instructions so you do not take too many, however.Juicing is very popular these days, and it is a great way to consume healthy vegetables and fruits. Many people add a powdered mineral and vitamin supplement to their juice drink to create a healthy breakfast smoothie they can enjoy every day. Also helps Increase Penis Size energy levels, even though this drink is not only very healthy.The best way to get vitamins and minerals is through your diet. To ensure you are getting what you need, add plenty of superfoods to your diet. Superfoods are high in a variety of vitamins and minerals. These foods includeblueberries and broccoli, leafy green vegetables, whole grains and many other foods.If you are taking iron or zinc, be sure not to take it at the same time as your calcium supplements. Calcium stops the absorption of the other two minerals when they are in the intestine together, and that defeats the whole purpose of taking those supplements. Just take them a few hours apart.Not all multivitamins are created equal. In fact, you need to be checking to ensure that the list of vitamins and minerals included in the multivitamin account for 100 percent of your daily allowances. Therefore, you are ensuring that you are getting all the essential nutrients that you should be getting from a multivitamin.Zinc may be the supplement you need if you are losing your hair. Zinc deficiency leads to hair loss, which means that ensuring you have enough in your system can help you to stop further thinning of your hair. Just pick up a supplement and add it to your daily regimen.If you find that taking your supplements leaves you feeling nauseous, be sure to take them with food. Taking minerals and vitamins on an empty stomach can easily upset it, so just take them with a meal instead. In fact, splitting them up amongst your meals can boost absorption.If you bought them online, make sure that you check the expiration date on any vitamins you purchases, especially. There are many people that sell vitamins at an ultra low rate because they are not supposed to be sold at all. Taking old supplements is not good since they will not be as effective as they should be.When taking vitamin supplements, always read the label to determine the amount of the vitamin included in each capsule or tablet.The best choice will usually be an amount that is close to the standard recommended daily dose. Before you buy, carefully consider the potential risk of high dose vitamins to the potential benefits.Selenium is found in crab, wheat, liver, fish and poultry. This potent mineral is used to treat blood vessel and heart diseases, including atherosclerosis and stroke. Studies have shown selenium can help prevent stomach, lung, prostate and skin cancers. Finally, selenium is used to treat CFS, hypothyroidism, macular and RA degeneration.Omega-3 supplements might be just what you need if you are feeling depressed. While people who have a diet high in fish will have plenty of these fatty acids in their body, those who don't eat much fish may be deficient. You can get more Omega-3s in fortified eggs or through supplements.If you find that taking your supplements leaves you feeling nauseous, be sure to take them with food. Taking vitamins and minerals on an empty stomach can easily upset it, so just take them with a meal instead. In fact, splitting them up amongst your meals can boost absorption.Now you know the basics when it comes to using minerals and vitamins to better your health. The next step is to figure out exactly what health issues you need to tackle and which supplements will do the job. Keep reading and learning and soon you'll feel better than ever!


text:
Current Planning
The current planning function involves the review of all development and subdivision proposals in the City for conformance with the adopted general plan, adopted specific plans, zoning, and subdivision regulations. This review includes projects ranging from simple room, patio, and pool plans to large scale subdivision, commercial, and industrial projects.
Most types of simple projects, such as pools, patio covers, room additions, signs, and tenant improvements, require only a counter check prior to approval.
More complex projects typically require submittal of a land use application (conditional use permit, tentative map, site plan review) for review.
Certain projects, including almost all subdivision requests, require review and approval of the City Planning Commission.
It is strongly suggested that prospective applicants contact the Planning Department to discuss potential projects to verify the review and approval process that will be required. Land use application forms are available for download from this website.
Processing time for various types of applications can only be estimated and are dependent on a variety of factors, including the department workload, completeness and accuracy of the submitted information, the need for modifications to the proposed plans to meet City development requirements, and the level of environmental review required.
Development proposals on vacant land typically require submittal of various environmental studies, including a biological assessment, a cultural resources assessment, and hazardous materials assessment.
It is the responsibility of the project applicant to submit these studies at the time the land use application is filed with the Department. The project applicant should contact the Department with any specific questions regarding a project site.


text:
Development and testing of protein backbone torsional potentials for the Kirkwood Buff derived force field of peptides and proteins
August 28, Fri 2009
1:00 pm, MRB 200 Conference Room
Dr. Feng Chen
Kansas State University
Recently, we have been developing a force field for biomolecular simulations of peptides and proteins (KBFF) designed to reproduce the experimental Kirkwood-Buff (KB) integrals observed in solution mixtures. This ensures a reasonable balance between solute-solute interactions and solute solvation – usually by water. Here, we describe the development and testing of the backbone torsion potentials, required for accurate modeling of the conformational preferences of amino acids, which are consistent with the corresponding KBFF nonbonded parameters. Molecular dynamics (MD) simulations were performed for dipeptides of glycine, alanine in solutions. Comparisons with crystallographic data and quantum mechanics derived gas phase energy surfaces are also made.


text:
Tips for Brixton South Bay
246 Brixton South Bay Tips
Great Price on Beer and Food by the vendor there!
Casual works there or a bit dressy either way goes!
Parking easy, just bring your receipt to pay upstairs!
Goldstar Member
Nice venue!
Lisa Loeb with Jill Sobule
Close easy parking in the parking structure, ubder the venue
Reasonable in price
Parking right close by
Get here early, and bring friends so you can share a table
Pink Floyd
Keep it comimg.. Looks like you got something good going on here. I HEARD good things about
Why don't you have this deal at your place... or do you own both of them?
I live close by. so a brisk walk in the night air was great!!
It's a "Beach House" maybe a Tux (If you're trying to get laid"
Drinks are decent priced
Easy parking at pier lot
Ample parking
Only some of the tables are with the $60 tab. y


text:
The Number 1 Way For Success in Reaching Your Dog Training Goals
by Debby Quigley
Whether you are training your dog to perform tricks, tasks, agility or obedience, it is done in stages. Debby Quigley explains how setting goals- milestones gives you a greater chance for success.
Establishing Goals is an incredible method for achieving what you want. Setting goals provides you with a way to view your objectives and make changes so that your goals can be met. Goals can be set for daily, weekly, monthly or yearly target dates. Setting goals focuses your attention to the important aspects of your mission and desires. The key to setting goals is to create goals that are objective and achievable and that can be measured to give you direction.
When setting goals, many people typically focus on learning new skills or performances in competitions. However, goals can cover many aspects of your training and life. Some examples of achievable goals include improving your fitness, or increasing your mental toughness, or improving your better timing and consistency, etc.
The old adage, "there are only so many hours in a day" so it makes sense to optimize your time on achieving your goals. Before you start thinking about what you want to achieve, you have to realistically determine exactly how much time and effort you are willing to devote to training and working towards your goal. The result of your time and effort will be reflected in your dog's ability to learn and execute skills consistently.
Here is a simple way to establish your goal(s) after you have determined the amount of time you are going to spend.
1. Ask yourself what DO YOU want to work toward and achieve. You goal needs to be under your control, challenging yet realistic and positive. Positive goals help you determine what you can do rather than what not to do! Make your goal(s) very specific. The clearer you objectives are, the easier it will be to imagine and obtain your goal. Effective goals are limited in number and importance to you. Establishing a few, carefully selected goals will allow you to keep accurate records without becoming overwhelmed.
2. Write down your goal. You can put your goals on sticky notes and post them where your will see them throughout the day. Place a sticky note on the fridge or your bathroom mirror or an index card in your training bag or car. Visual cues increase the likelihood you will achieve your goal.
3. Break down your long-term goals into small steps that can be used as short-term goals. Short-term goals can provide more motivation since they are more readily achievable and make great stepping stones. Short-term goals also show you the progress you have made towards obtaining the long-term goal.
4. Create action steps for each goal. These steps help you achieve your goal and will define the actions you need to take, study, train, or practice to reach your goal. The number of action steps depends on the goals you set.
5. Set specific Time Lines and Target Dates. Target dates have a tendency to remove lighthearted ideas and clarify which of your goals are realistic and which are not. Furthermore, Target dates give you a specific time frame to work towards.
6. Track your progress. Use a notebook, calendar, or anything you can log information so you can monitor your progress. Writing down and reviewing your progress will help you stay motivated and repeatedly remind you of where you were and how far you have come.
7. Celebrate your success for each step, short term- and long-term goal achieved. Remember it is the action steps that get you to your final goal
When carefully thought out and written, goals give direction and tell us what we need in order to accomplish our dreams.
About the author: Debby Quigley has been showing and teaching over 25 years in many venues including obedience, rally, agility, and scentwork. She has earned multiple OTCHs, MACHs, PACHs and perfect 200 scores. Debby also owns and teaches classes at Dogwood Dog Training in Houston, Tx and also teaches online at https://debbyquigley.com.


text:
specialized RBX comp cycling jersey
Free Online Advertising
Free Internet Web Site Advertising.
UK Free Classifieds
United Kingdom Free Ads Website.
100% Free Ad Posting.
Canada Free Ads
Popular Online Classifieds in Canada.
No Sign up, No Email Required to Post.
This is a specialized RBX comp cycling jersey Our website is dedicated to the sale of cheap Jerseys Suitable:men Size information: S, M, L, XL, XXL We offer a variety of discounts, you can be sure to buy in the online store:https://www.specializedshorts.com/specialized-rbx-comp-bib-short-kit-c-3_6.html
|Target Nation: All Nations
Target City : All Cities
Last Update : 22 July 2019
Number of Views: 48
|Item Owner : nian
Contact Email: (None)
Contact Phone: (None)
|Friendly reminder: Click here to read some tips.


text:
Chronixx sizzles on stage at Kingston stop of Chronology Tour
Chronixx performs at Mass Camp in Kingston on Friday night. (PHOTOS: Marlon Reid)
Chronixx brought a potpourri of souls to Mass Camp in Kingston on Friday evening for his Chronology Tour concert and kept them captive with titillating music.
Patrons left the venue in the wee hours of Saturday morning, in awe of a stellar performance.
The young reggae artiste gave the sold-out venue hits after hits from his expanding catalogue, including from his latest released, critically-acclaimed album, 'Chronology'.
Chronixx did a bit of everything during his performance – he sang, deejayed, danced, lectured and joked for the appreciative audience comprised of individuals of different races, ages and social and economic strata of the Jamaican society, as well as visitors from overseas.
His nearly two-and-a-half-hour set also had him drawing from past and present entertainers for inspiration, with most of these coming from the 1980s to early 1990s, when the 25-year-old would not have been born or was just a toddler.
During his act, he constantly reminded the crowd that he was born and raised in the volatile community of Spanish Town, specifically Dela Vega City.
He also blended his own performance with that of other artistes including Jah9, Protoje, Ravers Clavers and his father Chronicle, in a set that flowed smoothly from start to finish.
He performed 'Hardcore' with Jah9, 'Who Knows' with Protoje and 'Big Bad Sound' with father Chronicle who was the only guest to get a second song, a relatively unknown fun collaboration between the two.
Ravers Clavers joined him for his signature song from the 'Chronology' album, 'Likes', and performed the accompanying dance.
Chronixx, dressed in a white shirt with black stripes, a black jean pants and a black and white sneakers and hair tied in a bun, started his act from backstage at about 11:45 pm with the crowd cheering.
After appearing, he gave the crowd 'Ain't No Giving In' and 'They Don't Know' to which he asked the crowd to sing with him and they obliged. He would then give a Rastaman greeting during which he told audience members that 'queens' are the centre of all creations, before launching into 'Queen Majesty'.
He then delivered 'Black Is Beautiful', 'I Can' and 'Skankin' Sweet', during which he took the opportunity to pull his locks before doing 'Smile Jamaica' and 'Capture Land'. He would then introduce 'Ghetto Paradise' by telling the crowd that although Jamaica is nice, they must still live to save a life.
In a section in which he called history lesson, he started with his own 'Spanish Town Rocking' during which he showed his versatility by deejaying, and singing Tracy Chapman's Sorry and Barrington Levy's 'Prison Oval Rock', on the same rhythm.
With the crowd lapping up the performance, he then instructed his backing band, Zinc Fence Redemption to change to the 'Taxi Riddim' and he deejayed Buju Banton's 'Driver', bringing the audience further glee, before changing back to the original rhythm and 'Spanish Town Rocking'.
At this stage, Protoje, who had performed a full set earlier, returned for 'Who Knows', with the ladies screaming on his reentry to the stage.
Chronixx told the crowd that many people are known for one song before telling them that VC's one well known song, 'His Deeds' might be better than any song that he has ever done. He started the first verse of that song, before launching into 'Loneliness' and afterwards worked the crowd into ecstasy with 'Warrior'.
'Nah Follow Nobody' would come next, after which he took Yellow Man's 'nobody move, nobody get hurt line' and started Super Cat's 'Nuff Man A Dead'. He asked the crowd if they wanted him to "mash up inna now" and, when they gave him the affirmative, he deejayed an original lyric in recently incarcerated Ninja Man's 1980s stammer-sounding style. The crowd loved it.
Chronixx would then take the line, "Gal a bend up inna nine and inna 10" from another incarcerated deejay, Vybz Kartel's 'Buck Up Inna', before telling the crowd about his own blend-up juice, before singing 'Spurlina, which had the crowd in stitches.
He would mellow the mood again, by doing 'Sell My Gun' and 'Curtains', which he had to restart, after the crowd went wild.
After Zinc Fence Redemption started the instrumentals to his monster hit 'Likes', he stopped them to talk to the crowd, before calling up Ravers Clavers for them to perform together.
He would then deliver 'Legend' before telling the audience that he doesn't eat many things that are sold outside his home and, because he was hungry, it was time to go home to eat, triggering rounds of laughter.
Chronixx closed his solid set at 2:20 am with 'Like A Whistle'. See photo highlights in slider below.


text:
FOLLOWING Boris Johnson's article on key apprenticeship measures, the Tory Leadership candidate met with Harlow MP's sixth Parliamentary Apprentice, Dan Swords, in Westminster today.
Writing in his column for The Telegraph, Boris described apprenticeships as "indispensable" and made a commitment that, if elected, he will "properly fund all manner of technical and vocational education – from FE colleges to apprenticeships".
Rob said: "It's brilliant that Boris has announced £4.6 billion extra for schools and colleges and, today, he expands on that with apprenticeships, saying they are the best route for young people.
"I was really proud he met my 6th apprentice, Dan Swords."
Dan Swords said: "It was fantastic to meet Boris earlier today. Like Rob, he is so passionate about apprenticeships and, if chosen as leader, will invigorate skills training in this country, helping to close the deficit.
"I'm so pleased that a potential future Prime Minister recognises that apprentices have futures just as bright as any university graduate and that they represent the very best of our country."
Popularity: 1% [?]


text:
THEY both wanted to raise up little voices for change, and the music that moved them was the same – hip hop.
"Hip-hop is truth and it's our time for us to tell these truths," says Alphabet Rockers founder Kaitlin Mcgaw.
Formed in 2007, the group from California comprises McGaw and music director Tommy Shepherd and their latest album, Rise Shine #Woke, has been nominated for a Best Children's Album 2018 Grammy.
The album was made in collaboration with thought leaders, activists, educators, children and families dedicated to challenging biases and creating a safer world for everyone.
All lyrics and music in the album are by McGaw and Shepherd.
"The hardest part of independently created music is never creativity — it's always financing and marketing. We are fortunate to have multiple foundations that support our work, as well as the opportunity for crowdsourcing to help us make these groundbreaking albums.
"Lyrics and creation for us are true play. We work with experts in the field to create each song, and as hip hop writers, the word play is always the most fun," says McGaw.
The album features McGaw and Shepherd, as well as children aged from 4 to 15. Also on the album are American youth poets and children and families across the US and refugee camps in Greece.
After a decade, their passion to create positive messages and modern beats to help children love who they are, fight bias, and celebrate differences still shines bright.
Says McGaw of their first show in 2008: "Our first show was at Dolores Park in San Francisco, and even though we had just released our first album, there were 400 people there! It was amazing to see how much hip hop and children's music made sense — families immediately got into the beats and kids loved the way we performed.
"That's when we learnt that kids mirror performers dancing — so if you have one hand on a mic, they will pretend they do, too!"
While it's all still original music, and the children and families involved are multicultural, McGaw says there has been some changes.
"Two years ago, we had to start writing about diversity and giving our audience a model for how to talk about race and difference.
"We tested the concepts, and then wrote and shaped our Grammy-nominated album, Rise Shine #Woke, with songs that help all of us stand up for one another.
"Other things that have changed is our show is hot! We have contemporary beats from Grammy-winning producer Street Symphony spun by DJ Wonway Posibul, hip hop choreography from Samara Atkins, inspirational videos, and impactful moments of audience connection."
When asked if there were any deniers to Alphabet Rockers' message, given the current political scenario, she says:
"We were on this path regardless of who would lead our country. America has buried truths and is tongue-tied to name our mistakes and true wrongdoings.
"Many of these issues take form in racial discrimination that continue as a daily and institutional injustice.
"Since the election, human rights are even more disregarded. We have to fight to be heard, and we have to teach ourselves how to speak up and out after years of tolerance and silence.
"We truly believe this is a part of the culture of childhood in our country, too. It's not fair to shield children from all bad things — and not talk, understand and work together on them — this in itself is a privilege for kids who are not experiencing discrimination and racism. And the result is raising children who don't think it exists.
"We've found even more bravery and openness since we clarified our messaging. Presenters are ready for real art to change the world.
"If folks aren't ready for us, we'll work with those who are, and let them come around in time."
Winning a Grammy is a dream for many artistes.
For McGaw, the nomination is a lifelong dream and accomplishment for Alphabet Rockets.
"But not just for us — for everyone who has worked on this album, from our 8-year-old singer on 'I'm Proud' to the women leaders from Spotlight: Girls who funded that song to serve all girls.
"We are no longer a band, we are a movement. And within us are the intentions of all of our children and families around the world who are seeking new possibilities for connection and change.
"And yes, it is FUN. Becoming a better person and working with others for change has so much joy in it. We bring joy to our most courageous conversations, and we are so excited to bring this to an international platform with this nomination."
The best children's album of 2018 winner will be announced at the 60th annual GRAMMY Awards Premiere Ceremony at Madison Square Garden on Sunday, Jan 28. Visit www.grammy.com for more information about the 60th GRAMMYs.
++ This article appeared in most part in the new straits times. https://www.nst.com.my/lifestyle/groove/2018/01/325114/rocking-solid-change


text:
My IRS Dispute is Going into Litigation. What are My Options?
When individual or business taxpayers have civil disputes with the IRS, the first steps toward resolution are taken with the IRS directly. The ultimate result, however, may be a decision by the agency that the taxpayer believes is incorrect or unjust.
If this has happened to you, you may be stuck with a large tax bill that you don't believe you owe. If you haven't obtained legal counsel, now is the time to get skillful and knowledgeable representation.
In our experience, the best way to obtain a favorable outcome in IRS disputes is to perform an in-depth investigation and resolve the issues through direct negotiation with the agency — generally the sooner the better.
Once you've reached an impasse with the IRS, your next step may be an appeal through the federal courts. Depending on your circumstances, however, there are four different courts that may potentially hear your claim, and you may have the option to make a strategic choice about which court is most favorable.
Civil tax litigation with the IRS can be conducted in any of the following four courts:
- The U.S. Tax Court: This is the most common court for taxpayer appeals, and the judges have special expertise in federal tax law. One big benefit is that you don't have to pay the disputed taxes before trial.
- The U.S. District Courts: If you've exhausted all of the IRS's administrative remedies, you can sue the IRS for a refund in the federal trial court where you live. One big benefit here is you can get a jury trial.
- The U.S. Bankruptcy Court: Filing Chapter 7, 11 or 13 bankruptcy gives the Bankruptcy Court the discretion to determine whether your tax assessment or an IRS tax lien is valid — and to discharge certain older tax liabilities.
- The U.S. Court of Federal Claims: This Washington, DC, court was set up for lawsuits against the government. You can sue for a refund like you can in the federal district courts.
Every tax problem has a solution. No matter which court is most favorable in your case, Frost & Associates is here to arm you with the facts, protect your rights and do all we can to achieve an advantageous resolution on your behalf.


text:
The NYSC Diaries (Entry 4)
What will the son of man not see in this camp? From both the sly, irritating, funny and not-so-funny comments that I have been managing to take in my stride,
So, Who's Still a Virgin on Game of Thrones?
There are plenty of differences between Game of Thrones and Lord of the Rings, but one specific difference does a good job of representing the whole of them: In Lord


text:
A shortage of IT talent will result in salary increases this year, according to the latest Global Salary Survey from recruitment consultancy Robert Walters.
The survey, which is in its 14th year, covers 24 countries and disciplines in which the consultancy specialises.
It found that business analysts with six or more years experience can anticipate increases of up to nine percent; those with four to six years experience up to six percent; and business analysts with one to three years experience up to seven percent.
"Business analysts are expected to be sought after as organisations focus on strategies to improve efficiencies," says Tom Derbyshire, Robert Walters manager of IT recruitment. "An anticipated shortage of this skill set is expected to result in salary increases for these professionals."
He says that as organisations continue to focus on business growth in 2013, there will be strong demand for IT professionals, as large programmes of work are being signed off.
The survey found that due to the high demand, IT professionals can expected multiple job offers, allowing them to negotiate top salaries and benefits.
Strong demand for IT talent is expected in the first half of the year, due to a slight pause in capital spending in Q3 and Q4 of 2012, and key projects that will need to be delivered before the end of the financial year.
In its market overview of Wellington, Robert Walters says the recruitment market continued to be affected by market-wide transformation and large organisational change in 2012.
The recruiter noted the formation of merged super ministries, and that two major banks had also completed large-scale integration of their core systems and infrastructure (ANZ and National).
"These changes resulted in a large number of IT professionals leaving their roles after a long tenure and struggling to find new positions because their skills had not moved with the market."
Robert Walters says that, in contrast, there was increased demand for contract business analysts, project and programme managers, and intermediate and senior developers within both the .NET and Java space.
"Experienced solutions and enterprise architects were also highly sought after as a number of organisations tried to ensure their technology solutions were in line with their business objectives."
The consultancy notes that, despite the demand for IT professionals across the market, organisations tended to be very specific when recruiting, preferring to wait for a good technical and cultural fit before hiring.
"This meant that recruitment processes were often lengthy, sometimes taking up to four to six weeks."
In general, salaries in 2012 were on a par with the rates paid in 2011. But Robert Walters is predicting strong demand in the first half of 2013.
Permanent salaries for CIOs will rise from $145,000-225,000 in 2012 to $150,000-250,000 in 2013, the consultancy predicts. Contract rates will rise from $140,000-200,000 to $150,000 to $200,000.
Next best paid in 2012 were enterprise architects, who would attract permanent rates on $140,000 to $210,000 in 2013, and $110,000 to $150,000 at contract rates.
Experienced .NET and Java developers will earn up to $80,000 on permanent salary, and a similar rate on contract.
Bottom of the pile were service desk/ desktop support/ applications support people with one to three years experience, who would earn up to $55,000 in permanent jobs, and up to $45,000 on contract.
The Auckland market overview says jobs were tight throughout 2012 as organisations continued to focus on business growth. There was a consistent demand for permanent IT professionals in the first half of the year but organisations had to focus on hiring contract staff in the second half, due to a severe lack of available candidates.
Business analysts with business process re-engineering experience were in extremely high demand, as were professionals with Microsoft technologies experience.
Toward the end of the year, there was increasing demand for business intelligence data analysts.
Robert Walter expects the shortage of available job seekers for permanent roles in 2013 will continue and, as a result, salaries are likely to increase.
"We expect the contract market to increase significantly in 2013 with a strong pipeline of requirements going into the year."
CIOs and CTOs top the list of likely permanent salaries at $150,000, with those on contract earning up to $190,000, the same as in 2012.
Next best paid are likely to be programme managers, at $130,000 (up to $150,000 on contract), followed by development managers (up to $130,000 in a permanent role) and experienced project managers (up to $120,000 in a permanent role).
Experienced .NET and Java developers will earn up to $110,000 in a permanent role (up to $100,000 on contract). As in Wellington, the lowest paid jobs will be for support people (up to $55,000 in a permanent role and up to $35,000 on contract).


text:
Who's Running The Pistons?
Categories | The Armchair Athletes
Filetype: MP3 - Size: 82.4MB - Duration: 1:00:00 m (192 kbps 44100 Hz)
From the admin area you can customize this box. For instance you can add Widgets and Buttons
You can optionally disable the freebox if you don't need it.


text:
Our MISTER INTERNATIONAL and MISTER GLOBAL embroidered sashes are the same quality as those we make for all our clients, including Miss Universe and Miss USA!
If you are looking for a sash for a pageant with a negotiated agreement with SashMe, please look in the "Pageant-Specific" area of our site for your pageant.
U.S. Shipping is included in the price.
United States - USPS Priority Mail
Canada - USPS International Priority Mail
INTERNATIONAL - Outside of U.S. or Canada, please contact us for a quote.
NORMAL ORIENTATION - Title is limited to 20 characters and spaces
VERTICAL ORIENTATION - Title is limited to 14 characters and spaces
OTHER DETAILS:Made from rich, bridal satin.
Sash IS hand-washable
Sash is 70 inches long by 4 inches wide
Changes to the options listed MAY cost extra, but please feel free to contact us. We make a lot of custom sashes and are confident we can get you exactly what you need.


text:
The pound struggled to break through the $1.30-mark yet again on Thursday, as a rebound in the dollar and an election manifesto from the opposition Labour Party that fuelled some profit-taking on the British currency.
In its fourth attempt to break through $1.30 in nearly two months, the pound struggled to gain momentum as investors moved to the sidelines before the Dec. 12 election.
Labour leader Jeremy Corbyn unveiled his party's election manifesto on Thursday, setting out radical plans to transform Britain with public sector pay rises, higher taxes on companies and a sweeping nationalisation of infrastructure.
Following the release of the manifesto, the pound edged 0.1% lower against a broadly resurgent dollar to $1.2908 and weakened against the euro at 85.74 pence. The currency had slipped to a five-day low of $1.2888 after Tuesday's televised debate in which Corbyn was seen to have performed better than expected.
Source : Reuters


text:
Search the Community
Showing results for tags 'compatible'.
Found 2 results
Master Plus Compatibility Error with ML360R
oc_or_bust posted a topic in Liquid CoolingMaster Plus Compatibility Error with ML360R Error: Master Plus program does not run after working once. Sequence of events: Install ML360R > Install Master Plus program > Update stock firmware > Restart PC > Partial error box appears > Uninstall/re-install Master Plus program > Restart PC > Error remains. Questions: How do I correct this issue? What is the error that's only partially displayed? Why is it only partially displayed? Why does this program detect my ARGB hub device, but the LED RGB program doens't? Why did this product never mention the software needed or where to download it? Why does my mouse from 2015 still not work? Why do I keep buying Corsair products? What is the answer to life?
What kind Of a case can I Use For my Desktop PC
Senuka Dinujaya posted a topic in CasesHI What Kind of a Case Can i use for my desktop pc.. 1. My cooling system is-(cooler master seidon 120XL -PC CPU Liquid Water Cooling System,) 2.My Motherboard is-(Gigabyte GA-Z97X-UD3H LGA 1150 Z97 Ultra Durable UEFI DualBIOS ATX Motherboard) 3.My Power supply is-(Cooler Master GX II - 550W 80 PLUS Bronze Power Supply with Non-Stop USB Charging) Please Reply me AS SOON AS YOU CAN.


text:
Sharing ten of my favourite room reveals from the One Room Challenge this Spring! These designers inspired me on all fronts!
We are want to say thanks if you like to share this post to another people via your facebook, pinterest, google plus or twitter account.
Right Click to save picture or tap and hold for seven second if you are using iphone or ipad.
Source by : lovecreatecelebrate.com


text:
Tax Attorney In Los Angeles CA Defending Your Rights
Vargas Law and lead attorney Paul Vargas deal with all tax dispute and consultation matters in Los Angeles. As a tax attorney in Los Angeles, Mr. Vargas represents clients with matters before the IRS, Board of Equalization, Employer Development Department, Franchise Tax Board, and the California Department of Tax and Fee Administration. Please contact our local County Office in Riverside or Orange.
Work With A Specialized Tax Ligitation Attorney
Tax laws for individuals and for businesses are complicated and complex. Through to use of a specialized tax litigation attorney, legal representation provided the experience and knowledge of this area of the law to address unfavorable audits, to reduce the amount owed to the IRS and to help prevent liens, wage garnishments, and levies that may be used by the IRS.
The Legal Representation Required
A tax dispute attorney at Vargas Law, APC, provides the expertise needed to guide individuals and business owners facing tax problems in Los Angeles, CA. Our experience in representing clients as a criminal tax defense attorney and corporate tax attorney includes matters before the Franchise Tax Board, the IRS, California Department of Tax and Fee Administration as well as the Employer Development Department and the Board of Equalization.
Our IRS tax attorney can work with you at any point in time, including consulting through our small business tax attorney to limit tax liabilities. This is also a service we also provide for individuals when facing decisions that have the potential to impact future taxes.
As a highly specialized tax law firm in the Los Angeles, CA, area, we represent the best interests of our clients. Our services include post tax assessment representation by a highly qualified tax dispute attorney to provide penalty abatement, setting up installment agreements and requesting Innocent Spouse relief.
If you require a property tax attorney or assistance with tax resolution services, talk to the experienced tax litigation attorney at Vargas Law, APC.
What We Do
Years of Experience
We represent Taxpayer clients in front of the United States Tax Court. Taxpayers may have received an unfavorable audit determination and taking their case to Court may be necessary.
Settle For Less Than What You Owe
We represent Taxpayers in the Offer in Compromise application and review process from start to finish. You may be able to reduce your tax owed to the IRS.
Representation for Levies, Liens, and Wage Garnishments
We help taxpayers remove and defend against IRS collection action such as liens, levies, and wage garnishments.
Being Proactive with Your Tax Debt
We represent taxpayers and encourage them to be proactive in stopping the IRS from collection action. We provide services such as penalty abatement, Innocent Spouse Relief, Installment Agreements, and more.
Do Not Let the IRS Auditors Take Advantage of You
We represent taxpayers both individual and business under IRS audit. The IRS auditors are very aggressive and representation is advised.
Understand Tax Law for your Individual or Business Needs
We help taxpayers understand and prepare for those events that have tax ramifications. We provide tax consulting for both individuals and business.
An Experienced Tax Lawyer
Paul Vargas has been representing individuals and entities for over 14 years.
Mr. Vargas graduated Cum Laude from Western Michigan Thomas M. Cooley Law School. Additionally, he holds a advanced tax law degree, known as a Tax LL.M., from Loyola Law School in Los Angeles, where he graduated with honors.
He has represented both individual and business clients in front of the United States Tax Court, Internal Revenue Service, California Franchise Tax Board, California Board of Equalization, California Department of Fee and Tax Administration, California Employer Development Department, and other tax authorities.
Mr. Vargas advised I take my tax matter to U.S. Tax Court where he represented me. I was very pleased with his communication and attention to detail. I was very happy with the result of the case
Jonathan K.
Your Tax Attorney In Los Angeles
Vargas Law and lead attorney Paul Vargas deal with all tax dispute and consultation matters in Los Angeles. As a tax attorney in Los Angeles, Mr. Vargas represents clients with matters before the IRS, Board of Equalization, Employer Development Department, Franchise Tax Board, and the California Department of Tax and Fee Administration. Please contact our local County Office in Riverside or Orange.
Tax Representation Services Provided By Experienced Tax Attorney In Los Angeles
A general list of the tax representation services we provide:
Tax Returns: Tax Preparation for both current tax years and prior unfilled tax year for both individuals and business;
Tax Collection Representation: representation before the IRS and other government tax authorities to understand your account and get into installment agreements;
Tax Removal: Offer in Compromise Applications; Penalty Abatements; Audit Reconsiderations; tax return amendments; and Collection Due Process Hearings
Tax Levy, Garnishment, or Lien Disputes;
Tax Audit Representation: IRS and other government tax authority Audits and Audit Appeals;
U.S. Tax Court Litigation; and
All Other Tax Disputes: Innocent Spouse Relief; Identity Theft, unfair IRS collection actions, and more.
Ask Our Tax Attorney In Los Angeles A Question
Why do I need to hire tax attorney?
Taxpayers' lives are busy. It is hard to deal with the IRS while there are other life responsibilities that take precedent. Tax attorneys can help ease the stress and take care of the tax case while the Taxpayer continues with their daily life. Additionally, tax attorneys understand the law and can better help defend the Taxpayer's rights against the IRS and other tax authorities. It is best the Taxpayer not represent themselves as the IRS and other government agents may take advantage of someone who may not understand their rights. Let our experienced tax attorney in Los Angeles take care of you.
What is an Offer in Compromise?
In short, an Offer in Compromise ("OIC") is an agreement between the Taxpayer and the IRS to pay less tax than the Taxpayer current tax liability.
What is the Offer in Compromise process?
We represent the Taxpayer from submission of the OIC application to the determination by the OIC agent reviewing the Taxpayer's application. The process involves our attorney reviewing the Taxpayer's financial statements and better understanding the Taxpayer's ability to present an offer. Once an offer is submitted, the OIC agents will review the application and make a determination on whether the Taxpayer can full pay, pay less than what is owed but more than what is offered, or accept the Taxpayer's offer outright.
How Do I know if I am eligible to send an offer in compromise application?
We provide a free consultation to speak with the Taxpayer to provide a better understanding of their financial situation and current tax account, and what those matters mean for an OIC application. We will not take any cases where it is our belief the Taxpayer is highly unlikely to have an offer accepted. In such cases, we will provide other possible options to minimize the burden from the IRS.
Are there other ways to minimize my tax liability besides an Offer in Compromise?
Yes. If there are penalties on the account, we may attempt a penalty abatement to remove penalties on the Taxpayer's account. The Taxpayer must show "reasonable cause" to have these penalties removed, which we can discuss with the Taxpayer in our initial consultation. There are other ways to minimize tax liabilities through Audit Reconsideration (opening a closed audit) or amending returns.
What can I do with liens, levies and garnishments?
Taxpayers must contact the IRS right away when the IRS submits any levies or garnishments. We will gladly represent the Taxpayer if such situations arise. We have been successful in removing garnishments and levies, but time is certainly of the essence. With regard to liens, there are options to remove liens from the County recorder and your credit report through other types of applications.
I just received an audit letter, what do I do and what is the process?
It is best to contact the government contact on the letter right away and request for more time to respond. We represent Taxpayers in all stages of audits. It is important you hire an attorney as some information that is being requested by the IRS could open up more issues that can subject the Taxpayer to more tax liability. We can provide you a consultation with regard to your audit matter.
I received a letter stating that I have to petition the U.S. Tax Court, what do I do?
A Taxpayer can petition the U.S. Tax Court only after receiving a Notice of Deficiency or a Notice of Determination (in some cases). A petition to the Tax Court is the last option the Taxpayer has before the assessment is final. It is important the Taxpayer has a tax attorney review the notices and best determine the strategy in Tax Court. We cannot stress enough that a Taxpayer faces an uphill battle when representing themselves before IRS Counsel or even the U.S. Tax Court judge. Please contact us for a consultation.


text:
How to Care for Poinsettia?- 5 Rules to Swear By Poinsettia is a vital part of Christmas tradition. The best thing about these plants is that they can be displayed
Gardening Tips for Beginners- How to create your own garden?
It is a well- known fact that gardening is no longer limited to the countryside as well as urban areas. It is fast becoming the most preferred hobby among city-dwellers
Creative Ways to Plant a Vertical Garden
Vertical gardening is nothing more than deploying vertical space to produce vegetables (or herbs, or flowers, even root crops), often using containers that hang on a sunny wall. Traditional gardeners
DIY – Planting Adenium Seeds
Make your surrounding beautiful and maintain the positive vibes, the flowers can help you get the positivity at your place. Adenium plant is not just known for their beautiful looks
Me And My Garden
As a child lived in large bungalows, surrounded by greenery, I never did gardening but saw it happening all around me- observed fruits, flowers, vegetables, rice growing, watched trees, shrubs
Lessons Learnt From Pottery
We are all the same but yet a few of us stand out in the crowd of humans. It is their passion that gives them an identity. Gardening linked with
How To Make A DIY Pig Pot Planter
Need to spruce up your living space? Do you feel like your surroundings don't match up to your quirky fun personality? Don't worry, we've got you covered. This DIY pig
Living in congested and dull urban spaces often
Earthly Creations Brings To You Feng Shui Essentials For Your Home And Office
Good Feng shui helps you create an environment at home and in the office that will strengthen you, support your desire and attract the feng shui energies of prosperity and


text:
Located between Béziers and Agde, in heart of the Languedoc, the vineyard Preignes and its medieval castle belongs to the same family of winemakers : The Vic Family. 5 generations have succeeded each other to produce renowned wines, typical by an unique basaltic terroir.
Syrah, et « une pointe » de Grenache
Clay-gravel and volcanic
Vines are ploughed. We do not use weedkiller Pruning is short to regulate the vine's growth and its grapes yields
The vines shoots are are tied up along vires to be given the favourable angle to ripen the grapes. The grapes are picked up by machines at the best maturity. The stalks are taken off to avoid vegetal tastes.
The whole grapes are placed in vats. The process of fermentation starts naturally. It starts with the juice that runs from burst grapes and also takes place into each grape. The skin and juice contact lasts no more than 8 hours, then we separate the juice. It allows a nice extraction of fruit flavours and colour.
Fresh. 8-10 °C
Ideal with grilled rib steak, tuna and herbs or crayfish
Bouteille 75cl
Pale pink. Nose marrying violet and wonderful minerality. The palate reveals surprising vivacity, fullness and exuberance.
Votre navigateur n'est pas jour!
Par conséquant, nous ne pouvons garantir une bonne expérience sur notre site internet.Mettre à jour mon navigateur.


text:
I'm one of those annoying people who take deadlines really, really seriously. Last year I accidentally prepared two tax returns because I did the first one so far in advance of the deadline that I clean forgot that I had already done it. So I find the "last minute" working style both perplexing and frightening. And yet, in recent weeks, I have had to stand by, helpless, and watch it happen in the most important arena: legislation.
As I wrote a few days ago, the UK's Criminal Finances Act 2017 has just been passed. I had been tracking it day by day from the beginning – when it had its first reading in the Commons on 13 October 2016 – and could see that it was going to be close. Of course, the closeness was not part of the plan: the date of prorogation (the closing of a session of parliament, at which point, to put it simply, Bills must become Acts or fall by the wayside) was abnormally affected by the announcement of the coming General Election. And so the race was on: would the Lords be able to debate all their proposed amendments and send them back to the Commons for approval before prorogation? As you know, they did, and for the most part, it has worked out as we had anticipated.
Not so for the (confusingly similarly named) Finance Act 2017 ("a Bill to grant certain duties, to alter other duties, and to amend the law relating to the national debt and the public revenue, and to make further provision in connection with finance"). This one started on its legislative journey much more recently – on 14 March 2017 – and so the sudden looming appearance of prorogation had a more drastic effect on it. As you can see here, in this handy table showing which bits survived and which were sacrificed in the name of expediency. You will note that of the original 135 clauses, 72 were removed in order to push the legislation through – that's 53% of them, and presumably they're the tricky ones that might have held things up. The slimline Finance Act 2017 did receive Royal Assent on 27 April 2017, but I'm not sure I am comfortable with the way that parliamentary timetabling can trump (please can we reclaim that word?) original legislative intentions.